3D printer Materialise buys orthopedic software co; FDA clears first medical device with a game mode;

@FierceMedDev: Siemens in talks to sell hearing aids biz for $2.6B+. More | Follow @FierceMedDev

@VarunSaxena2: GSK exec stresses need to move away from 'fragmented' approach to drug delivery. Story | Follow @VarunSaxena2

@EmilyWFierce: Roche plots $3.2B overhaul at Basel HQ, joining parade of Big Pharma building projects. Article | Follow @EmilyWFierce

@MichaelGFierce: Encapsulated #Alzheimers, #Parkinsons-treating growth factors implanted directly in the brain | Follow @MichaelGFierce

> 3D printing company Materialise ($MTLS) acquired Orthoview, an orthopedic digital pre-operative planning software company for up to as much as about £9 million ($14.4). Release

> XPRIZE announced 11 finalists for its $2.25M Nokia Sensing XCHALLENGE, a competition to develop breakthrough medical sensing technologies tto enable faster diagnoses and easier personal health monitoring. Release

> An inexpensive, disposable external medical device to monitor uterine contractions in pregnant women has launched. It's marketed as the Koala Toco by Clinical Innovations. Story

> The FDA cleared Avacen Medical's joint pain relief medical device that uses a game mode to keep patients with attention difficulties engaged for the duration of physical therapy. It's the first medical device that's gotten through the agency to include a game feature, the company said. Release

Biotech News

@FierceBiotech: Viamet drops IPO, spins out cancer drug as ex-Elan chief funds $60M round. More | Follow @FierceBiotech

@JohnCFierce: Kelly Martin (Elan) is ba-a-a-ack. Viamet drops IPO, spins out cancer drug as ex-Elan chief funds $60M round. | Follow @JohnCFierce

@DamianFierce: Have to applaud $ABBV's vanity url game, securing HepC.com right in $GILD's face. Article | Follow @DamianFierce

@EmilyMFierce: $JNJ gives the Ebola vaccine push a $200M boost. News | Follow @EmilyMFierce

> Proteon banks $61M in a down-sized IPO as it moves on without Novartis. More

> Roche blueprints a sprawling $1.8B R&D complex for pRED. Article

> Regulus soars on promising--but early--results for its hep C contender. News

Pharma News

@FiercePharma: Top-read special report Monday: The top 10 most expensive drugs of 2013. More | Follow @FiercePharma

@EricPFierce: ICYMI: India's Ascend sold laxatives to urea creams the #FDA never approved. It's now headed for incineration. Story | Follow @EricPFierce

@CarlyHFierce: Boehringer revs up Ofev sales force, support services to rival Roche's Esbriet in IPF. Article | Follow @CarlyHFierce

> GlaxoSmithKline sets $1.6B in new cost cuts, thanks in part to Advair's U.S. formulary discounts. More

> Spinoff fervor grows: GSK looks at ViiV spinoff and investor tells Amgen to break things up. Story

> GSK dealmaking spawns management shake-up, putting Slaoui and Hussain in top slots. News

Drug Delivery News

> Encapsulated Alzheimer's, Parkinson's-treating growth factors implanted directly in the brain. News

> Highland pulls in $25M for night-dosed morning ADHD treatment. Story

> Encapsulation of fecal matter achieved for treatment of infected colons. More

> Sanofi leads $11M Series A round for needle-free delivery company. Report

> GSK exec stresses need to move away from 'fragmented' approach to drug delivery. Article

Diagnostics News

> Quest and LabCorp won't accept blood samples from suspected Ebola patients. Story

> Xagenic names CEO to help commercialize lab-free molecular Dx tech. Report

> Celgene takes equity stake in Sequenta and its precise Dx tech. News

> BioMérieux subsidiary nails Medicare coverage for breast cancer molecular test. Article

> Virginia Tech finds possible biomarker for rare immunodeficiency condition. Item

Pharma Marketing News

> Is your DTC campaign working? New program tracks viewers from TV to pharmacy. Report

> Cancer survivor's petition pleads with Roche for lower Kadcyla price. News

> GlaxoSmithKline puts emerging markets chief Hussain in charge of global pharma ops. More

> Advair sales slide triggers another $1.6 billion in cost cuts at GlaxoSmithKline. Article

> Novartis recruits Nick Cannon for double-whammy flu campaign. Report